Patents by Inventor Jill Taylor

Jill Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240116801
    Abstract: A colored glass article includes greater than or equal to 50 mol % and less than or equal to 80 mol % SiO2; greater than or equal to 7 mol % and less than or equal to 25 mol % Al2O3; greater than or equal to 1 mol % and less than or equal to 15 mol % B2O3; greater than or equal to 5 mol % and less than or equal to 20 mol % Li2O; greater than or equal to 0.5 mol % and less than or equal to 15 mol % Na2O; greater than 0 mol % and less than or equal to 1 mol % K2O; and greater than or equal to 1×10?6 mol % and less than or equal to 1 mol % Au. R2O—Al2O3 is greater than or equal to ?5 mol % and less than or equal to 7 mol %, R2O being the sum of Li2O, Na2O, and K2O.
    Type: Application
    Filed: December 13, 2023
    Publication date: April 11, 2024
    Inventors: Xiaoju Guo, Jill Marie Hall, Karl William Koch, III, Jesse Kohl, Jian Luo, Liping Xiong Smith, Nicole Taylor Wiles
  • Publication number: 20110223659
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: December 7, 2010
    Publication date: September 15, 2011
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • Patent number: 7846655
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: December 7, 2010
    Assignee: Diagnostic Hybrids, Inc.
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • Publication number: 20080076115
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: November 3, 2004
    Publication date: March 27, 2008
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • Patent number: 7144578
    Abstract: Recombinant viruses containing DNA coding for a rabies virus antigen, such as rabies virus G are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom are useful for eliciting an immunological against rabies virus, and, the gene products and antibodies elicited thereby are useful in assays.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: December 5, 2006
    Assignee: Connaught Technology Corporation
    Inventors: Enzo Paoletti, James Tartaglia, Jill Taylor, Russell Gettig
  • Patent number: 7129042
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: October 31, 2006
    Assignees: Diagnostic Hybrids, Inc., Health Research Incorporated
    Inventors: Laura Gillim-Ross, Jill Taylor, David R. Scholl, David E. Wentworth, Joseph D. Jollick
  • Publication number: 20050095582
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: November 3, 2003
    Publication date: May 5, 2005
    Applicants: Diagnostic Hybrids, Inc., Health Research Incorporated
    Inventors: Laura Gillim-Ross, Jill Taylor, David Scholl, David Wentworth, Joseph Jollick
  • Publication number: 20030082204
    Abstract: Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen or measles M or N antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein, canine distemper virus hemagglutinin glycoprotein, canine distemper nucleocaspid portein, canine distemper matrix protein, measles virus nucleocaspid protein, and measles virus matrix protein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus and/or measles virus, and, the gene products and antibodies elicited thereby are useful in assays. Additionally, DNA from the recombinants is used for probes or for generating PCR primers.
    Type: Application
    Filed: September 13, 2001
    Publication date: May 1, 2003
    Applicant: Aventis Pasteur.
    Inventors: Enzo Paoletti, James Tartaglia, Jill Taylor, Russell Gettig
  • Patent number: 6309647
    Abstract: Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen or measles M or N antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein, canine distemper virus hemagglutinin glycoprotein, canine distemper nucleocaspid protein, canine distemper matrix protein, measles virus nucleocaspid protein, and measles virus matrix protein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus and/or measles virus, and, the gene products and antibodies elicited thereby are useful in assays. Additionally, DNA from the recombinants is used for probes or for generating PCR primers.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: October 30, 2001
    Assignee: Aventis Pasteur
    Inventors: Enzo Paoletti, James Tartaglia, Jill Taylor, Russell Gettig
  • Patent number: 5957765
    Abstract: A portable power tool comprises a housing, a motor with a driving mechanism for a cylindrical tool for sanding, rasping of filing a workpiece, and means for guiding and supporting the power tool on the workpiece surface. The driving mechanism includes means for rotating and oscillating the output shaft and the tool. The oscillating means includes a wobbling swash plate which is fixed to an intermediate shaft at a slant angle thereto, and follower means engaging the wobbling swash plate. When the intermediate shaft and the swash plate rotate, the follower means reciprocates to oscillate the tool along the output shaft axis.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: September 28, 1999
    Inventors: Erich Kimbel, Gerd Buchter, Jill Taylor
  • Patent number: 5891442
    Abstract: What is described is a recombinant poxvirus, such as fowlpox virus, containing foreign DNA from infectious bursal disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 6, 1999
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Jill Taylor, Russell Gettig
  • Patent number: 5766599
    Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 16, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe Francis Audonnet, Russell Robert Gettig
  • Patent number: 5762938
    Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: June 9, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe Francis Audonnet, Russell Robert Gettig
  • Patent number: 5759552
    Abstract: What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.
    Type: Grant
    Filed: March 7, 1994
    Date of Patent: June 2, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Jill Taylor, James Tartaglia, Louis Ross
  • Patent number: 5759553
    Abstract: What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 2, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Jill Taylor, James Tartaglia, Louis Ross
  • Patent number: 5759841
    Abstract: What is described is a recombinant poxvirus, such as vaccinia virus or canarypox virus, containing foreign DNA from Morbillivirus. In one embodiment, the foreign DNA is expressed in a host by the production of a measles virus glycoprotein. In another embodiment, the foreign DNA is expressed in a host by the production of at least two measles virus glycoproteins. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. By the present invention, cross-protection of dogs against canine distemper is obtained by inoculating the dog with the recombinant poxvirus.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 2, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Jill Taylor
  • Patent number: 5756103
    Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 26, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe Francis Audonnet, Russell Robert Gettig
  • Patent number: 5756102
    Abstract: Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein and canine distemper virus hemagglutinin glycoprotein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus.
    Type: Grant
    Filed: April 6, 1994
    Date of Patent: May 26, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, James Tartaglia, Jill Taylor
  • Patent number: 5685301
    Abstract: The apparatus of the present invention characterizes the operating characteristics of a medical monitoring probe in a more comprehensive and accurate manner than is heretofore known in the prior art. This apparatus not only identifies the present value of a plurality of operating characteristics of the optical components contained in the probe, but also computes the interrelationship therebetween to produce a composite probe indicia that substantially defines the net operating characteristics of the probe, including the interrelation of the various interactive and/or cumulative effects. This composite probe indicia represents either a number or a graphical representation of probe operating characteristics that can be used directly by the processor contained within the monitoring system to perform the required computations.
    Type: Grant
    Filed: June 16, 1995
    Date of Patent: November 11, 1997
    Assignee: Ohmeda Inc.
    Inventor: Jill Taylor Klomhaus
  • Patent number: D814291
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: April 3, 2018
    Inventor: Jill Taylor